Sk Biopharmaceuticals Co Ltd (KO:326030) — Stock Price
Sk Biopharmaceuticals Co Ltd (KO:326030) is currently trading at ₩88700.00 KRW, up 3.86% today. Over the past 52 weeks, shares have ranged between ₩74600.00 and ₩140700.00. This page tracks Sk Biopharmaceuticals Co Ltd's live share price on the KO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Sk Biopharmaceuticals Co Ltd market cap and net worth.
Sk Biopharmaceuticals Co Ltd (326030) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Sk Biopharmaceuticals Co Ltd's daily closing share price and trading volume on the KO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Sk Biopharmaceuticals Co Ltd Income Statement — Revenue, Profit & Earnings by Year
Sk Biopharmaceuticals Co Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | ₩706.74 Billion | ₩547.60 Billion | ₩354.89 Billion | ₩246.18 Billion | ₩418.64 Billion |
| Cost of Revenue | ₩42.90 Billion | ₩43.10 Billion | ₩34.08 Billion | ₩37.77 Billion | ₩22.34 Billion |
| Gross Profit | ₩663.84 Billion | ₩504.50 Billion | ₩320.81 Billion | ₩208.41 Billion | ₩396.31 Billion |
| Research & Development | ₩174.34 Billion | ₩161.27 Billion | ₩137.13 Billion | ₩122.82 Billion | ₩114.53 Billion |
| SG&A | ₩146.29 Billion | ₩114.79 Billion | ₩101.87 Billion | ₩112.32 Billion | ₩89.80 Billion |
| Total Operating Expenses | ₩502.80 Billion | ₩451.26 Billion | ₩392.41 Billion | ₩377.26 Billion | ₩323.69 Billion |
| Operating Income | ₩203.94 Billion | ₩96.34 Billion | ₩-37.52 Billion | ₩-131.08 Billion | ₩94.96 Billion |
| EBITDA | — | — | — | ₩-125.77 Billion | ₩83.87 Billion |
| EBIT | — | — | — | ₩-131.08 Billion | ₩94.96 Billion |
| Interest Expense | ₩7.69 Billion | ₩10.68 Billion | ₩8.28 Billion | ₩3.72 Billion | ₩946.98 Million |
| Income Before Tax | ₩150.88 Billion | ₩72.60 Billion | ₩-43.86 Billion | ₩-142.47 Billion | ₩71.28 Billion |
| Income Tax Expense | — | — | — | ₩-3.04 Billion | ₩6.43 Billion |
| Net Income | ₩266.95 Billion | ₩240.74 Billion | ₩-32.88 Billion | ₩-139.43 Billion | ₩64.85 Billion |
Sk Biopharmaceuticals Co Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Sk Biopharmaceuticals Co Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | ₩1.20 Trillion | ₩1.04 Trillion | ₩723.17 Billion | ₩664.24 Billion | ₩643.65 Billion |
| Total Current Assets | ₩683.23 Billion | ₩651.37 Billion | ₩488.72 Billion | ₩487.92 Billion | ₩471.22 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | ₩1.71 Billion | ₩1.68 Billion | ₩1.42 Billion | ₩201.39 Billion | ₩108.42 Billion |
| Net Receivables | ₩228.83 Billion | ₩173.82 Billion | ₩111.00 Billion | ₩63.51 Billion | ₩55.88 Billion |
| Inventory | ₩100.24 Billion | ₩111.68 Billion | ₩102.53 Billion | ₩90.92 Billion | ₩51.93 Billion |
| Property, Plant & Equipment | — | — | — | ₩20.35 Billion | ₩22.94 Billion |
| Goodwill | ₩1.65 Billion | ₩1.69 Billion | ₩3.39 Billion | — | — |
| Total Liabilities | ₩372.04 Billion | ₩462.83 Billion | ₩402.22 Billion | ₩347.68 Billion | ₩199.46 Billion |
| Total Current Liabilities | ₩295.20 Billion | ₩396.28 Billion | ₩241.62 Billion | ₩163.07 Billion | ₩148.31 Billion |
| Long-term Debt | — | — | ₩94.48 Billion | ₩143.72 Billion | — |
| Net Debt | — | — | — | ₩39.66 Billion | — |
| Total Stockholder Equity | ₩813.04 Billion | ₩546.27 Billion | ₩283.69 Billion | ₩316.56 Billion | ₩444.19 Billion |
| Retained Earnings | ₩-354.14 Billion | ₩-621.53 Billion | ₩-861.56 Billion | ₩-827.56 Billion | ₩-689.14 Billion |
Sk Biopharmaceuticals Co Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Sk Biopharmaceuticals Co Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩176.33 Billion | ₩94.90 Billion | ₩-94.20 Billion | ₩-159.92 Billion | ₩-92.87 Billion |
| Capital Expenditures | ₩29.51 Billion | ₩13.42 Billion | ₩3.25 Billion | ₩4.91 Billion | ₩4.32 Billion |
| Free Cash Flow | ₩146.82 Billion | ₩81.48 Billion | ₩-97.45 Billion | ₩-165.88 Billion | ₩-98.86 Billion |
| Investing Cash Flow | — | — | — | ₩-95.71 Billion | ₩258.97 Billion |
| Financing Cash Flow | — | — | — | ₩134.91 Billion | ₩-4.65 Billion |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | ₩3.63 Billion | ₩7.51 Billion | ₩3.23 Billion | ₩60.66 Million | ₩416.71 Million |
| Depreciation | ₩16.95 Billion | ₩17.43 Billion | ₩15.32 Billion | ₩12.98 Billion | ₩11.64 Billion |
| Change in Cash | ₩-15.04 Billion | ₩83.11 Billion | ₩135.64 Billion | ₩-121.86 Billion | ₩166.59 Billion |
Sk Biopharmaceuticals Co Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Sk Biopharmaceuticals Co Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 07, 2026 | — | 492.58 | — |
| Mar 09, 2026 | 1744.00 | 434.02 | +301.82% |
| Nov 13, 2025 | 947.00 | 342.46 | +176.53% |
| Aug 14, 2025 | 420.00 | 390.33 | +7.60% |
| May 08, 2025 | 298.00 | 355.53 | -16.18% |
| Mar 07, 2025 | 2428.00 | 197.19 | +1131.30% |
| Nov 14, 2024 | 123.00 | 123.44 | -0.36% |
| Aug 14, 2024 | 359.00 | 107.24 | +234.76% |